Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells

  • Marianna Lucafò
  • Sabrina Pacor
  • Chiara Fabbro
  • Tatiana Da Ros
  • Sonia Zorzet
  • Maurizio Prato
  • Gianni Sava
Research Paper

Abstract

Fullerenes (C60) represent important carbon nanoparticles, widely investigated for diagnostic and therapeutic uses, mainly because they are characterized by a small size (between 7 and 10 Å) and a large surface area. The cytotoxicity of two fullerene derivatives, functionalized by 1,3-dipolar cycloaddition of azomethine ylides to the C60 cage (1 and 2), the mechanism of cellular uptake (studied with a fluorescein-bearing derivative of 1, hereafter called derivative 3), and the intracellular distribution are the subject of this work. Cell cytotoxicity on human mammary carcinoma cell line (MCF7), evaluated with the MTT test and further confirmed by a flow cytometry approach with DiOC6 and PI probes, showed that derivative 1 was free of necrotic or apoptotic effects even after a long lasting cell exposure. Cell uptake and internalization of derivative 3 reach their zenith within 12 h after treatment, with a tendency to persist up to 72 h; this process was evaluated by flow cytometry and confirmed by confocal microscopy. Thus, it appears that a compound such as derivative 1 may be unspecifically taken up by MCF7 cells, in which it distributes throughout the cytoplasm, apparently avoiding any co-localization within the nucleus and secretory granules. These results suggest a strong interaction between the tested fullerene and mammalian cells and a significant ability of this compound to enter tumor cells, therefore resulting to be a suitable vector to deliver anticancer agents to tumor cells.

Keywords

Fullerene Nanoparticle Cytotoxicity Cellular uptake Anticancer drug delivery Nanomedicine 

References

  1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398CrossRefGoogle Scholar
  2. Bosi S, Da Ros T, Spalluto G, Prato M (2003) Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 38(11–12):913–923CrossRefGoogle Scholar
  3. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S (2009a) Shape effect of carbon nanovectors on angiogenesis. ACS Nano 4(1):574–582CrossRefGoogle Scholar
  4. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S (2009b) Fullerenol cytotoxic conjugates for cancer chemotherapy. ACS Nano 3(9):2505–2514CrossRefGoogle Scholar
  5. Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15(2):153–172CrossRefGoogle Scholar
  6. Dellinger A et al (2010) Uptake and distribution of fullerenes in human mast cells. Nanomedicine 6:575–581CrossRefGoogle Scholar
  7. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 14 57(15):2215–2237CrossRefGoogle Scholar
  8. Duvvuri M, Krise JP (2005) Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10:1499–1509CrossRefGoogle Scholar
  9. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, Seta P, Larroque C (2002) Cellular localization of a water-soluble fullerene derivative. Biochem Biophys Res Commun 294(1):116–119CrossRefGoogle Scholar
  10. Gorczyca W (1999) Cytometric analyses to distinguish death processes. Endocr Relat Cancer 6:17–19CrossRefGoogle Scholar
  11. Gotink K, Broxterman HJ, Labots M, De Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17(23):7337–7346CrossRefGoogle Scholar
  12. Guldi DM, Maggini M, Scorrano G, Prato M (1997) Intramolecular electron transfer in fullerene/ferrocene based donor-bridge-acceptor dyads. J Am Chem Soc 119:974–980CrossRefGoogle Scholar
  13. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–818CrossRefGoogle Scholar
  14. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368–377CrossRefGoogle Scholar
  15. Kessel D, Wilberding C (1984) Mode of action of calcium antagonists which alter anthracycline resistance. Biochem Pharmacol 33(7):1157–1160CrossRefGoogle Scholar
  16. Kordatos K, Da Ros T, Bosi S, Vazquez E, Bergamin M, Cusan C, Pellarini F, Tomberli V, Baiti B, Pantarotto D, Georgakilas V, Spalluto G, Prato M (2001) Novel versatile fullerene synthons. J Org Chem 66:4915–4920CrossRefGoogle Scholar
  17. Kordatos K, Da Ros T, Prato M, Bensasson VR, Leach S (2003) Absorption spectra of monoaduct and eight bisadduct regioisomers of pyrrolidine derivatives of C60. Chem Phys 293:263–280CrossRefGoogle Scholar
  18. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM (2009) Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials 30:2112–2121CrossRefGoogle Scholar
  19. Levi N, Hantgan RR, Lively MO, Carroll DL, Prasad GL (2006) C60-fullerenes: detection of intracellular photoluminescence and lack of cytotoxic effects. J Nanobiotechnol 4(4):14CrossRefGoogle Scholar
  20. Lu F, Haque ASK, Yang ST, Luo PG, Gu L, Kitaygorodskiy A, Li H, Lacher S, Sun YP (2009) Aqueous compatible fullerene–doxorubicin conjugates. J Phys Chem 113:17768–17773Google Scholar
  21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284CrossRefGoogle Scholar
  22. Maggini M, Prato M (1998) Fulleropyrrolidines: a family of full-fledged fullerene derivatives. Acc Chem Res 31(9):519–526CrossRefGoogle Scholar
  23. Maggini M, Scorrano G, Prato M (1993) Addition of azomethine ylides to C60: synthesis, characterization and functionalization of fullerene-pyrrolidines. J Am Chem Soc 115:9798–9799CrossRefGoogle Scholar
  24. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392Google Scholar
  25. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311–330CrossRefGoogle Scholar
  26. Monteiro-Riviere NA, Inman AO, Zhang LW (2009) Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 234:222–235CrossRefGoogle Scholar
  27. Partha R, Conyers JL (2009) Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomed 4:261–275CrossRefGoogle Scholar
  28. Partha R, Mitchell LR, Lyon J, Joshi PP, Conyers JL (2008) Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery. ACS Nano 2(9):1950–1958CrossRefGoogle Scholar
  29. Surendiran A, Sandhiya S, Pradhan SC, Adithan C (2009) Novel application of nanotechnology in medicine. Indian J Med Res 130:689–701Google Scholar
  30. Tattersall M, Clarke S (2003) Developments in drug delivery: implications for cancer care. Curr Opin Oncol 15:293–299CrossRefGoogle Scholar
  31. Vail SA, Krawczuk PJ, Guldi DM, Palkar A, Echegoyen L, Tomé JPC, Fazio MA, Schuster DI (2005) Energy and electron transfer in polyacetylene-linked zinc-porphyrin-[60]fullerene molecular wires. Chem Eur J 11:3375–3388CrossRefGoogle Scholar
  32. Worle-Knirsch JM, Pulskamp K, Krug HF (2006) Oops they did it again! carbon nanotubes hoax scientists in viability assays. Nano Lett 6:1261–1268CrossRefGoogle Scholar
  33. Zhanga LW, Yang J, Barron AR, Monteiro-Riviere NA (2009) Endocytic mechanisms and toxicity of a fullerene in human cells. Toxicol Lett 191:149–157CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Marianna Lucafò
    • 1
  • Sabrina Pacor
    • 1
  • Chiara Fabbro
    • 2
  • Tatiana Da Ros
    • 2
  • Sonia Zorzet
    • 1
  • Maurizio Prato
    • 2
  • Gianni Sava
    • 1
  1. 1.Department of Life SciencesUniversity of TriesteTriesteItaly
  2. 2.Department of Chemical and Pharmaceutical SciencesUniversity of TriesteTriesteItaly

Personalised recommendations